Meneldor offers her customers the unique opportunity to invest alongside specialists, in exciting early stage up to and including phase 2 Biotech and Pharma companies. A sector often considered as very risky and highly complex. Meneldor thoroughly studies the science behind her potential portfolio companies. If the science is sound, then all other key aspects; IP, medical need, addressable markets, competition, risk, management, financial needs, valuation, etc., are assessed. Only if a target company meets our selection criteria, Meneldor will invest and invite her investors to participate.